Is ABUS or SLBT more profitable?

ABUS runs the higher net margin — ABUS at 84.23% versus SLBT at -173.85%.

Arbutus Biopharma Corp (ABUS) vs SL Science Holding Ltd (SLBT)

A side-by-side comparison of Arbutus Biopharma Corp and SL Science Holding Ltd across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ABUS

Arbutus Biopharma Corp

$885M

$4.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SLBT

SL Science Holding Ltd

$869M

$1.55HealthcareDelayed quote: Oct 6, 2026, 3:54 PM EDT

Total return — ABUS vs SLBT

growth of $100 · dividends reinvested · last 1y

ABUS +7.4% (+7.4%/yr)SLBT -79.6% (-79.6%/yr)ABUS compounded faster over this window

Log scale — wide-divergence pair

ABUS SLBT

ABUS vs SLBT: by the numbers

•ABUS is the larger company ($885M vs $869M market cap).
•ABUS is profitable (84.23% net margin) while SLBT runs a net loss (-173.85%).

Metrics side by side

Valuation

Metric	ABUS	SLBT
P/E ratio	5.74	N/A
Forward P/E	6.05	N/A
P/S ratio	4.87	N/A
P/B ratio	3.42	380.49
EV / EBITDA	5.90	N/A

Profitability

Metric	ABUS	SLBT
Gross margin	99.98%	35.27%
Operating margin	-192.08%	-174.65%
Net margin	84.23%	-173.85%
ROE	59.16%	-167.25%
ROIC	54.39%	-163.39%

Growth (annualized)

Metric	ABUS	SLBT
Revenue CAGR (5Y)	85.17%	N/A
Total return CAGR (5Y)	2.19%	N/A

Frequently asked

Is ABUS or SLBT more profitable?: ABUS runs the higher net margin — ABUS at 84.23% versus SLBT at -173.85%.

Go deeper

Full ABUS analysis Full SLBT analysis Interactive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratio Arbutus Biopharma ROE SL Science ROE Arbutus Biopharma operating margin SL Science operating margin Arbutus Biopharma revenue growth SL Science revenue growth Arbutus Biopharma free cash flow SL Science free cash flow

Arbutus Biopharma & SL Science appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.